Parliament of Canada (2023). Government Bill S-5: Strengthening Environmental Protection for a Healthier Canada Act
This legislative document outlines the amendments to the Canadian Environmental Protection Act (CEPA), including the recognition of the right to a healthy environment and the mandate to develop alternative testing strategies. However, its operational scope is strictly limited to chemical toxicity and environmental contaminants, explicitly excluding biomedical research and drug discovery, which highlights a critical gap in Canada’s comprehensive transition away from animal testing. ↩︎

Corporate Knights (2024). Canada’s Plan to Phase Out Animal Testing Suffers a Setback
This article discusses the significant delays and bureaucratic hurdles facing Canada’s strategy to replace, reduce, or refine vertebrate animal testing under CEPA. It highlights how the lack of dedicated federal funding and the closure of key alternative testing centers, like the CCAAM, have severely undermined the country’s ability to meet its own legislative goals and keep pace with international advancements in New Approach Methodologies (NAM). ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

Environment and Climate Change Canada (2025). Strategy to replace, reduce or refine vertebrate animal testing under CEPA
This government strategy document details the framework for implementing the animal testing reduction mandates introduced by Bill S-5. While it outlines goals for developing and adopting alternative methods for chemical safety assessments, critics note that its discretionary language and lack of binding timelines or dedicated external funding mechanisms limit its practical impact and fail to address the broader biomedical research sector. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

Food and Drug Administration (2026). General Considerations for the Use of New Approach Methodologies (NAMs) in Drug Development (Draft Guidance)
This pivotal FDA draft guidance establishes a flexible, fit-for-purpose regulatory framework for submitting NAM data in support of Investigational New Drug (IND) and New Drug Application (NDA) submissions. By clarifying that formal validation against legacy animal data is not a mandatory precondition, the guidance significantly lowers the barrier to entry for human-relevant technologies like organ-on-a-chip and advanced in vitro models, accelerating their adoption in pharmaceutical development. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

Animal Wellness Action (2025). FDA Modernization Act 3.0 Fact Sheet
This fact sheet details the provisions of the FDA Modernization Act 3.0, which builds upon the groundbreaking 2.0 legislation by further solidifying the regulatory acceptance of New Approach Methodologies. It emphasizes the continued shift away from mandatory animal testing, promoting the integration of advanced computational models, human cell-based assays, and microphysiological systems as primary tools for ensuring drug safety and efficacy. ↩︎ ↩︎ ↩︎

ONTOX Consortium (2025). AI-driven Safety Assessment and REACH Compliance
The ONTOX project, funded under the EU’s Horizon Europe program, represents a major collaborative effort to develop and validate AI-driven, non-animal methods for chemical safety assessment. This initiative aims to create a comprehensive, next-generation risk assessment framework that aligns with REACH compliance requirements, demonstrating Europe’s proactive, well-funded approach to phasing out animal testing in regulatory toxicology. ↩︎ ↩︎ ↩︎ ↩︎

European Commission (2023). Horizon Europe Work Programme
This document outlines the strategic research and innovation funding priorities of the European Union for the Horizon Europe framework. It highlights significant financial allocations specifically dedicated to consortia developing advanced in vitro, in silico, and microphysiological models, underscoring the EU’s commitment to driving systemic, top-down transitions toward human-relevant, animal-free biomedical and toxicological research. ↩︎ ↩︎

Transition Programme for animal-free Innovation (2022). TPI Netherlands Strategic Agenda and Goals
This strategic agenda outlines the Dutch government’s comprehensive, top-down approach to eliminating animal testing through the Transition Programme for Innovation (TPI). Unlike frameworks that merely focus on the “Three Rs,” the TPI is explicitly dedicated to the complete Replacement of animal models, fostering strong public-private partnerships and accelerating the clinical translation of advanced, human-relevant technologies. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

Fouad, K. & Lavelle, K. (2025). Stepwise Imperatives for Improving the Protection of Animals in Canadian Science
This academic paper critically examines the current regulatory landscape governing animal research in Canada, identifying significant flaws in the self-regulated system managed by the Canadian Council on Animal Care (CCAC). The authors propose a series of stepwise legislative and policy reforms, including the establishment of binding federal laws and centralized oversight, to improve animal welfare and accelerate the adoption of alternative, non-animal methodologies. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

National Institutes of Health (2026). NIH Invests $150 Million in Human-Based Research to Reduce Use of Animal Models
This announcement details the NIH’s landmark $150 million investment through the Complement-ARIE program, designed to catalyze the development and regulatory adoption of New Approach Methodologies. By funding dedicated Technology Development Centers, a centralized Data Hub, and a Validation and Qualification Network, the NIH is creating a robust, ring-fenced infrastructure that bypasses traditional, animal-biased granting loops. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

National Institutes of Health (2026). Complement-ARIE: Catalyzing the development and adoption of new approach methodologies
This resource provides a detailed overview of the Complement-ARIE initiative, highlighting its mission to transform preclinical research by prioritizing human biology over animal models. It outlines the program’s structured approach to fostering collaboration between academia, industry, and regulatory agencies to ensure that emerging NAM technologies are rigorously validated, standardized, and seamlessly integrated into the drug development pipeline. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

Lund Stem Cell Center (2026). Lund Joins €4.5M Horizon Europe Network for Advanced Human Brain Models
This press release announces the participation of the Lund Stem Cell Center in the VISI-ON-BRAIN network, a €4.5 million Horizon Europe initiative. The project focuses on developing and validating advanced, human-relevant brain models, such as organoids and microphysiological systems, to study neurological disorders and assess drug toxicity, exemplifying the EU’s targeted investment in next-generation, animal-free research infrastructure. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

Utrecht University (2024). Dutch National Growth Fund invests 124.5 million in transition to animal-free innovation
This announcement details the landmark €124.5 million investment by the Dutch National Growth Fund into the Centre for Animal-Free Biomedical Translation (CPBT), also known as the Ombion Centre. This public-private partnership aims to accelerate the development, validation, and implementation of human-relevant research models across all Dutch academic medical centers, solidifying the Netherlands’ position as a global leader in animal-free innovation. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

National Institute for Public Health and the Environment - RIVM (2024). Dutch National Growth Fund CPBT Investment
This RIVM report elaborates on the strategic allocation of the National Growth Fund’s investment into the CPBT. It emphasizes the centre’s role in bridging the gap between academic research and biotechnology infrastructure, providing a stable, long-term funding mechanism that enables the scalable development and regulatory acceptance of advanced in vitro and in silico models for biomedical applications. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

University of Windsor (2024). The Defunct Canadian Centre for Alternatives to Animal Methods
This entry documents the unfortunate closure of the Canadian Centre for Alternatives to Animal Methods (CCAAM) at the University of Windsor in 2024. Due to a complete lack of sustained federal funding and reliance on short-term grants, the centre was forced to shutter, representing a catastrophic loss of Canada’s only dedicated national infrastructure for developing and validating non-animal research methodologies. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

Nolte, M. (2025). ZonMw Promoting Research into Animal-Free Methods under MKMD
This article highlights the proactive role of ZonMw, the Dutch health research and development organization, in promoting animal-free research through its Mission-Driven Innovation in Healthcare (MKMD) program. By explicitly formulating granting calls that reject animal data as the “gold standard” and prioritize validation against human clinical outcomes, ZonMw is actively dismantling the traditional validation bottleneck. ↩︎ ↩︎ ↩︎ ↩︎

Animal Alliance Advisory Group on Humane Science (2022). Critical Review of the Canadian Council on Animal Care (CCAC)
This critical review exposes the systemic weaknesses and conflicts of interest inherent in the Canadian Council on Animal Care (CCAC), which currently operates as a self-regulated body overseeing animal research in Canada. The report argues that the CCAC’s voluntary guidelines, lack of enforcement power, and inherent bias toward maintaining the status quo actively hinder the adoption of New Approach Methodologies and compromise animal welfare. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

Taylor, K. & Griffin, G. (2019). Analyzing Animal Use Protocol (AUP) Forms Across Canadian Institutions
This study analyzes the Animal Use Protocol (AUP) forms used by Canadian research institutions, revealing significant deficiencies in how the “Three Rs” (Replacement, Reduction, Refinement) are evaluated and enforced. The findings demonstrate that current forms fail to elicit sufficient information to ensure that researchers have genuinely considered or exhausted non-animal alternatives, highlighting a critical flaw in Canada’s ethical oversight of animal research. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

Fortune Business Insights (2025). Global Organs-on-Chips Market Size and Trends
This market research report provides a comprehensive analysis of the global organs-on-chips industry, projecting explosive growth to reach nearly $2 billion USD by 2034. It identifies North America as the dominant market, driven primarily by robust federal investments and favorable regulatory shifts, underscoring the massive economic opportunity that Canada risks forfeiting by failing to invest in this transformative technology. ↩︎ ↩︎ ↩︎ ↩︎

MarkNtel Advisors (2025). Global Organ-on-Chip Market (2025-2030)
This industry analysis forecasts a compound annual growth rate (CAGR) of over 35% for the global organ-on-chip market through 2030. The report highlights the increasing adoption of these microphysiological systems by pharmaceutical and biotechnology companies seeking to reduce drug development costs, improve predictive accuracy, and comply with evolving regulatory mandates that favor human-relevant testing models. ↩︎ ↩︎ ↩︎

Grand View Research (2024). Organ-on-a-Chip Market Size, Share & Trends Analysis
This detailed market report segments the global organ-on-a-chip industry by product type, application, and end-user, confirming a strong upward trajectory driven by the urgent need to overcome the high failure rates of traditional animal models in clinical trials. It emphasizes that regions with proactive government funding and clear regulatory pathways for NAM are capturing the majority of this market’s economic and scientific benefits. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

Canadian Institutes of Health Research (2025). Peer Review Committee Mandates - Project Grant Program
This document outlines the evaluation criteria and mandates for CIHR’s Project Grant peer review committees. Critics argue that these committees inherently favor traditional, animal-based research methodologies due to entrenched academic biases and a lack of specific evaluation frameworks for New Approach Methodologies, thereby systematically downrating innovative, non-animal research proposals and perpetuating Canada’s scientific stagnation. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

Attitudes Toward Animal Research and Experimentation: An Annotated Bibliography 2011-2019. WellBeing International Studies Repository
This comprehensive bibliography compiles survey data and sociological studies regarding researcher attitudes toward animal experimentation. It highlights a growing consensus within the scientific community that reliance on animal models is a significant roadblock to reproducibility and reliability, with a substantial majority of researchers indicating they would consider emigrating to countries with more progressive, well-funded, and animal-free research policies. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

Utrecht Science Park (2025). Ombion Centre for Animal-free Biomedical Translation celebrates launch
This announcement marks the official launch and site opening of the Ombion Centre at Utrecht Science Park, a cornerstone of the Dutch National Growth Fund’s investment in animal-free innovation. The centre serves as a global education and research hub, offering specialized training, interdisciplinary challenges, and state-of-the-art facilities to equip the next generation of scientists with expertise in NAM and microphysiological systems. ↩︎

Animal Diseases and Alternatives Association (2024). Canada’s Regulatory Holdup on Non-Animal Methods
This advocacy report details the bureaucratic delays and regulatory inertia that have stalled the implementation of Canada’s promised strategy for replacing animal testing under CEPA. It highlights the frustration of researchers and advocacy groups who are actively petitioning the government to expedite the process, provide dedicated funding, and expand the scope of alternative methods to include biomedical research. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

HU University of Applied Sciences Utrecht (2024). 125 million euros from National Growth Fund for animal-free biomedical innovation
This institutional update highlights the role of the HU University of Applied Sciences Utrecht as a key partner in the €124.5 million National Growth Fund initiative. It emphasizes the university’s commitment to developing a Professional Master’s program in Animal-Free Innovation, directly addressing the global skills deficit by training students in the practical application of advanced, human-relevant research technologies. ↩︎

Booker, C. & Paul, R. (2022). Passage of the FDA Modernization Act 2.0
This article celebrates the historic passage of the FDA Modernization Act 2.0, detailing the bipartisan legislative effort that successfully removed the decades-old statutory mandate for animal testing in the Food, Drug, and Cosmetic Act. It explains how this landmark legislation legally equates New Approach Methodologies with traditional animal studies, fundamentally modernizing the US pharmaceutical R&D paradigm. ↩︎

CDER (2025). The Roadmap and Subsequent FDA Preclinical Study Actions (FDAMA 2.0 & 3.0)
This Center for Drug Evaluation and Research (CDER) document outlines the FDA’s strategic roadmap for implementing the provisions of the FDA Modernization Acts 2.0 and 3.0. It details the agency’s ongoing efforts to develop clear guidance, foster interagency collaboration, and actively encourage pharmaceutical sponsors to incorporate human-relevant NAM into their preclinical safety and efficacy testing packages. ↩︎ ↩︎

Utrecht Science Park (2025). Ombion Centre for Animal-free Biomedical Translation celebrates launch
This announcement marks the official launch and site opening of the Ombion Centre at Utrecht Science Park, a cornerstone of the Dutch National Growth Fund’s investment in animal-free innovation. The centre serves as a global education and research hub, offering specialized training, interdisciplinary challenges, and state-of-the-art facilities to equip the next generation of scientists with expertise in NAM and microphysiological systems. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

Johns Hopkins University & New York University (2026). NIH Complement-ARIE Technology Development Centers and Data Hub
This collaborative announcement details the establishment of the Technology Development Centers and the NAM Data Hub under the NIH’s Complement-ARIE program. It highlights the critical role of these academic institutions in creating a centralized, federated database for NAM-related data, developing analytical tools, and fostering a pre-competitive environment to accelerate the validation and dissemination of human-relevant testing methods. ↩︎ ↩︎ ↩︎

HU University of Applied Sciences Utrecht (2024). 125 million euros from National Growth Fund for animal-free biomedical innovation
This institutional update highlights the role of the HU University of Applied Sciences Utrecht as a key partner in the €124.5 million National Growth Fund initiative. It emphasizes the university’s commitment to developing a Professional Master’s program in Animal-Free Innovation, directly addressing the global skills deficit by training students in the practical application of advanced, human-relevant research technologies. ↩︎ ↩︎ ↩︎

Health Canada (2024). CMP Horizontal Initiative Funding Allocation under Budget 2024
This government document details the allocation of funds within the Chemicals Management Plan (CMP) Horizontal Initiative. While it mentions financial support for advancing scientific research to phase out animal toxicity testing, the funding is directed internally to support Health Canada’s own regulatory assessment activities, conspicuously failing to establish any external, dedicated capital pools to support academic researchers or independent national validation infrastructure. ↩︎

Studna, A. (2026). FDA Issues Draft Guidance to Validate Non-Animal Testing Methods
This industry analysis examines the FDA’s recent draft guidance aimed at streamlining the acceptance of non-animal testing methods in drug development. It emphasizes how the guidance’s “fit-for-purpose” framework empowers sponsors to submit robust mechanistic and human clinical data in lieu of traditional animal validation, significantly reducing regulatory uncertainty and accelerating the adoption of innovative NAM. ↩︎ ↩︎ ↩︎

National Centre for the 3Rs (2025). Incorporating new approach methodologies in the development of new medicines
This comprehensive guide, published by the UK’s National Centre for the 3Rs, provides practical strategies and case studies for integrating New Approach Methodologies into the pharmaceutical development pipeline. It serves as a vital resource for researchers and regulators, demonstrating how human-relevant models can be effectively utilized to improve predictive toxicology, reduce animal use, and enhance the overall quality of preclinical data. ↩︎ ↩︎

Canadian Council on Animal Care (2022). CCAC Annual Animal Data Report Analysis
This report analyzes the CCAC’s annual animal use data, revealing a troubling trend: despite decades of promoting the “Three Rs,” the total number of animals used in Canadian research has continued to rise. Alternative method advocates cite this data as definitive proof that the CCAC’s voluntary, self-regulated framework is fundamentally ineffective at driving meaningful reduction or replacement of animal models. ↩︎

Doctors Against Animal Experiments (2025). Developing a global education hub for animal-free innovation
This article highlights international efforts, particularly in the Netherlands, to establish dedicated global education hubs for animal-free innovation. It underscores the critical importance of integrating NAM, such as microphysiological systems and computational toxicology, into standard university curricula to prevent degree devaluation and ensure that the next generation of scientists is equipped with modern, competitive skills. ↩︎ ↩︎ ↩︎ ↩︎

Berridge BR. (2021). Animal Study Translation: The Other Reproducibility Challenge, ILAR Journal, 2021.
This article highlights the critical challenge of translating findings from animal studies to human applications, framing it as a distinct “reproducibility crisis” alongside the well-known issue of failing to reproduce results within the same species. The author argues that poor translatability stems from fundamental biological differences between models and humans, urging the research community to prioritize understanding these translational barriers and developing better predictive models to improve the success rate of drug development. ↩︎ ↩︎

Animal Free Science Advocacy (2025). Landmark Roadmaps and Funding Endorsements for alternative testing globally
This advocacy report compiles and analyzes recent landmark roadmaps and funding commitments from governments and regulatory agencies worldwide that endorse the transition to alternative testing methods. It contrasts the robust, well-funded, and legally binding progress seen in regions like the EU and the US with Canada’s continued stagnation, serving as a call to action for Canadian policymakers to modernize their regulatory and funding frameworks. ↩︎ ↩︎ ↩︎